| Characteristics . | SATELLITE patients . | Non-SATELLITE patientsa . | |
|---|---|---|---|
| . | OAC (N = 944) . | Received rhythm treatment strategies N = 575 . | N = 12 388 . |
| Demographics, n (%) | |||
| Age (years), median (IQR) | 69.0 (61.0–76.0) | 67.0 (59.0–75.0) | 71.0 (63.0–78.0) |
| Male | 553 (58.6) | 337 (58.6) | 7259 (58.6) |
| Race | |||
| White | 857 (90.8) | 517 (89.9) | 10 570 (85.4) |
| Black/African American | 35 (3.7) | 21 (3.7) | 637 (5.1) |
| Other | 52 (5.5) | 37 (6.4) | 1168 (9.4) |
| Insurance | |||
| Private | 557 (59.0) | 336 (58.4) | 6362 (51.4) |
| Medicare | 333 (35.3) | 207 (36.0) | 4753 (38.4) |
| Other | 54 (5.7) | 32 (5.6) | 1273 (10.3) |
| Risk factors, n (%) | |||
| Congestive heart failure | 203 (21.5) | 123 (21.4) | 2664 (21.5) |
| Non-ischaemic cardiomyopathy | 150 (15.9) | 86 (15.0) | 1700 (13.8) |
| Functional status: NYHA Class I | 68 (7.2) | 38 (6.6) | 855 (6.9) |
| Stroke | 42 (4.4) | 19 (3.3) | 790 (6.4) |
| AF at most recent 12-lead ECG | 483 (51.2) | 270 (47.0) | 6141 (49.6) |
| Prior MI | 96 (44.2) | 55 (43.0) | 1261 (38.1) |
| Prior CABG | 69 (31.8) | 43 (33.6) | 1107 (33.5) |
| Hypertension | 711 (75.3) | 417 (72.5) | 9886 (79.8) |
| Diabetes | 248 (26.3) | 147 (25.6) | 3237 (26.1) |
| COPD | 112 (11.9) | 67 (11.7) | 1394 (11.3) |
| Hyperlipidaemia | 573 (60.7) | 340 (59.1) | 8007 (64.6) |
| CHA2DS2-VASc score, n (%) | |||
| Low: 0 | 49 (5.2) | 37 (6.4) | 503 (4.1) |
| Medium: 1 | 131 (13.9) | 91 (15.8) | 1327 (10.7) |
| High: 2+ | 764 (80.9) | 447 (77.7) | 10 557 (85.2) |
| ORBIT score, n (%) | |||
| Low: 0–2 | 679 (75.9) | 414 (76.7) | 7967 (69.8) |
| Moderate: 3 | 111 (12.4) | 66 (12.2) | 1685 (14.8) |
| High: 4+ | 105 (11.7) | 60 (11.1) | 1759 (15.4) |
| ATRIA score, n (%) | |||
| =0 | 143 (15.1) | 105 (18.3) | 1515 (12.2) |
| =1 | 365 (38.7) | 221 (38.4) | 4269 (34.5) |
| =2 | 50 (5.3) | 24 (4.2) | 612 (4.9) |
| ≥3 | 386 (40.9) | 225 (39.1) | 5992 (48.4) |
| Characteristics . | SATELLITE patients . | Non-SATELLITE patientsa . | |
|---|---|---|---|
| . | OAC (N = 944) . | Received rhythm treatment strategies N = 575 . | N = 12 388 . |
| Demographics, n (%) | |||
| Age (years), median (IQR) | 69.0 (61.0–76.0) | 67.0 (59.0–75.0) | 71.0 (63.0–78.0) |
| Male | 553 (58.6) | 337 (58.6) | 7259 (58.6) |
| Race | |||
| White | 857 (90.8) | 517 (89.9) | 10 570 (85.4) |
| Black/African American | 35 (3.7) | 21 (3.7) | 637 (5.1) |
| Other | 52 (5.5) | 37 (6.4) | 1168 (9.4) |
| Insurance | |||
| Private | 557 (59.0) | 336 (58.4) | 6362 (51.4) |
| Medicare | 333 (35.3) | 207 (36.0) | 4753 (38.4) |
| Other | 54 (5.7) | 32 (5.6) | 1273 (10.3) |
| Risk factors, n (%) | |||
| Congestive heart failure | 203 (21.5) | 123 (21.4) | 2664 (21.5) |
| Non-ischaemic cardiomyopathy | 150 (15.9) | 86 (15.0) | 1700 (13.8) |
| Functional status: NYHA Class I | 68 (7.2) | 38 (6.6) | 855 (6.9) |
| Stroke | 42 (4.4) | 19 (3.3) | 790 (6.4) |
| AF at most recent 12-lead ECG | 483 (51.2) | 270 (47.0) | 6141 (49.6) |
| Prior MI | 96 (44.2) | 55 (43.0) | 1261 (38.1) |
| Prior CABG | 69 (31.8) | 43 (33.6) | 1107 (33.5) |
| Hypertension | 711 (75.3) | 417 (72.5) | 9886 (79.8) |
| Diabetes | 248 (26.3) | 147 (25.6) | 3237 (26.1) |
| COPD | 112 (11.9) | 67 (11.7) | 1394 (11.3) |
| Hyperlipidaemia | 573 (60.7) | 340 (59.1) | 8007 (64.6) |
| CHA2DS2-VASc score, n (%) | |||
| Low: 0 | 49 (5.2) | 37 (6.4) | 503 (4.1) |
| Medium: 1 | 131 (13.9) | 91 (15.8) | 1327 (10.7) |
| High: 2+ | 764 (80.9) | 447 (77.7) | 10 557 (85.2) |
| ORBIT score, n (%) | |||
| Low: 0–2 | 679 (75.9) | 414 (76.7) | 7967 (69.8) |
| Moderate: 3 | 111 (12.4) | 66 (12.2) | 1685 (14.8) |
| High: 4+ | 105 (11.7) | 60 (11.1) | 1759 (15.4) |
| ATRIA score, n (%) | |||
| =0 | 143 (15.1) | 105 (18.3) | 1515 (12.2) |
| =1 | 365 (38.7) | 221 (38.4) | 4269 (34.5) |
| =2 | 50 (5.3) | 24 (4.2) | 612 (4.9) |
| ≥3 | 386 (40.9) | 225 (39.1) | 5992 (48.4) |
No SATELLITE information provided at both baseline and follow-up periods.
| Characteristics . | SATELLITE patients . | Non-SATELLITE patientsa . | |
|---|---|---|---|
| . | OAC (N = 944) . | Received rhythm treatment strategies N = 575 . | N = 12 388 . |
| Demographics, n (%) | |||
| Age (years), median (IQR) | 69.0 (61.0–76.0) | 67.0 (59.0–75.0) | 71.0 (63.0–78.0) |
| Male | 553 (58.6) | 337 (58.6) | 7259 (58.6) |
| Race | |||
| White | 857 (90.8) | 517 (89.9) | 10 570 (85.4) |
| Black/African American | 35 (3.7) | 21 (3.7) | 637 (5.1) |
| Other | 52 (5.5) | 37 (6.4) | 1168 (9.4) |
| Insurance | |||
| Private | 557 (59.0) | 336 (58.4) | 6362 (51.4) |
| Medicare | 333 (35.3) | 207 (36.0) | 4753 (38.4) |
| Other | 54 (5.7) | 32 (5.6) | 1273 (10.3) |
| Risk factors, n (%) | |||
| Congestive heart failure | 203 (21.5) | 123 (21.4) | 2664 (21.5) |
| Non-ischaemic cardiomyopathy | 150 (15.9) | 86 (15.0) | 1700 (13.8) |
| Functional status: NYHA Class I | 68 (7.2) | 38 (6.6) | 855 (6.9) |
| Stroke | 42 (4.4) | 19 (3.3) | 790 (6.4) |
| AF at most recent 12-lead ECG | 483 (51.2) | 270 (47.0) | 6141 (49.6) |
| Prior MI | 96 (44.2) | 55 (43.0) | 1261 (38.1) |
| Prior CABG | 69 (31.8) | 43 (33.6) | 1107 (33.5) |
| Hypertension | 711 (75.3) | 417 (72.5) | 9886 (79.8) |
| Diabetes | 248 (26.3) | 147 (25.6) | 3237 (26.1) |
| COPD | 112 (11.9) | 67 (11.7) | 1394 (11.3) |
| Hyperlipidaemia | 573 (60.7) | 340 (59.1) | 8007 (64.6) |
| CHA2DS2-VASc score, n (%) | |||
| Low: 0 | 49 (5.2) | 37 (6.4) | 503 (4.1) |
| Medium: 1 | 131 (13.9) | 91 (15.8) | 1327 (10.7) |
| High: 2+ | 764 (80.9) | 447 (77.7) | 10 557 (85.2) |
| ORBIT score, n (%) | |||
| Low: 0–2 | 679 (75.9) | 414 (76.7) | 7967 (69.8) |
| Moderate: 3 | 111 (12.4) | 66 (12.2) | 1685 (14.8) |
| High: 4+ | 105 (11.7) | 60 (11.1) | 1759 (15.4) |
| ATRIA score, n (%) | |||
| =0 | 143 (15.1) | 105 (18.3) | 1515 (12.2) |
| =1 | 365 (38.7) | 221 (38.4) | 4269 (34.5) |
| =2 | 50 (5.3) | 24 (4.2) | 612 (4.9) |
| ≥3 | 386 (40.9) | 225 (39.1) | 5992 (48.4) |
| Characteristics . | SATELLITE patients . | Non-SATELLITE patientsa . | |
|---|---|---|---|
| . | OAC (N = 944) . | Received rhythm treatment strategies N = 575 . | N = 12 388 . |
| Demographics, n (%) | |||
| Age (years), median (IQR) | 69.0 (61.0–76.0) | 67.0 (59.0–75.0) | 71.0 (63.0–78.0) |
| Male | 553 (58.6) | 337 (58.6) | 7259 (58.6) |
| Race | |||
| White | 857 (90.8) | 517 (89.9) | 10 570 (85.4) |
| Black/African American | 35 (3.7) | 21 (3.7) | 637 (5.1) |
| Other | 52 (5.5) | 37 (6.4) | 1168 (9.4) |
| Insurance | |||
| Private | 557 (59.0) | 336 (58.4) | 6362 (51.4) |
| Medicare | 333 (35.3) | 207 (36.0) | 4753 (38.4) |
| Other | 54 (5.7) | 32 (5.6) | 1273 (10.3) |
| Risk factors, n (%) | |||
| Congestive heart failure | 203 (21.5) | 123 (21.4) | 2664 (21.5) |
| Non-ischaemic cardiomyopathy | 150 (15.9) | 86 (15.0) | 1700 (13.8) |
| Functional status: NYHA Class I | 68 (7.2) | 38 (6.6) | 855 (6.9) |
| Stroke | 42 (4.4) | 19 (3.3) | 790 (6.4) |
| AF at most recent 12-lead ECG | 483 (51.2) | 270 (47.0) | 6141 (49.6) |
| Prior MI | 96 (44.2) | 55 (43.0) | 1261 (38.1) |
| Prior CABG | 69 (31.8) | 43 (33.6) | 1107 (33.5) |
| Hypertension | 711 (75.3) | 417 (72.5) | 9886 (79.8) |
| Diabetes | 248 (26.3) | 147 (25.6) | 3237 (26.1) |
| COPD | 112 (11.9) | 67 (11.7) | 1394 (11.3) |
| Hyperlipidaemia | 573 (60.7) | 340 (59.1) | 8007 (64.6) |
| CHA2DS2-VASc score, n (%) | |||
| Low: 0 | 49 (5.2) | 37 (6.4) | 503 (4.1) |
| Medium: 1 | 131 (13.9) | 91 (15.8) | 1327 (10.7) |
| High: 2+ | 764 (80.9) | 447 (77.7) | 10 557 (85.2) |
| ORBIT score, n (%) | |||
| Low: 0–2 | 679 (75.9) | 414 (76.7) | 7967 (69.8) |
| Moderate: 3 | 111 (12.4) | 66 (12.2) | 1685 (14.8) |
| High: 4+ | 105 (11.7) | 60 (11.1) | 1759 (15.4) |
| ATRIA score, n (%) | |||
| =0 | 143 (15.1) | 105 (18.3) | 1515 (12.2) |
| =1 | 365 (38.7) | 221 (38.4) | 4269 (34.5) |
| =2 | 50 (5.3) | 24 (4.2) | 612 (4.9) |
| ≥3 | 386 (40.9) | 225 (39.1) | 5992 (48.4) |
No SATELLITE information provided at both baseline and follow-up periods.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
